Evaluation of cross-protection afforded by a Salmonella Choleraesuis vaccine against Salmonella infections in pigs under field conditions
Maes, D.; Gibson, K.; Trigo, E.; Saszak, A.; Grass, J.; Carlson, A.; Blaha, T.
Berliner und Münchener Tierärztliche Wochenschrift 114(9-10): 339-341
2001
ISSN/ISBN: 0005-9366 PMID: 11570172 Document Number: 530125
This field study investigated the efficacy of a S. choleraesuis live vaccine (Argus SCTM) to reduce the number of infections with Salmonella. 12 groups of about 380 pigs each were randomly allocated to either vaccination (V) or no vaccination (C). The vaccine was applied orally at 3 and 16 weeks. Blood was collected from 40 pigs/group at 3, 10, 16, and 24 weeks to detect possible antibodies against Salmonella. The prevalence of Salmonella in the lymph nodes was the major variable. In the V groups, only 0.6% of the lymph nodes were positive, whereas 7.2% were positive in the C groups (P<0.001). The percentage of seropositive pigs at 24 weeks (cut-off OD>10) was 26 and 9% in the V and C groups, respectively (P<0.001). The present study documented that vaccination with a live modified S. choleraesuis vaccine is a useful tool to lower the prevalence of Salmonella in swine herds.